Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

What's the BIOSECURE Act? Why is Merck nonchalant about Summit's Keytruda rival? What did Roivant buy from Bayer? We answer ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

While economic data may be scarce, every data point gives a new angle to the ever-uncertain economic conditions in the US.

Life sciences sector saw a drop in M&A deals in H1 2024, but values increased, with Johnson & Johnson (JNJ) leading the pack ...

The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...

Researchers described results as 'an important first step' in potentially developing new treatment for people with advanced ...

For instance, Merck’s Keytruda generated $25 billion in revenue last year alone. Even in its fourth year on the market, back ...

Pakistani police say they have arrested the key suspect in the gang rape of a woman polio worker who was assaulted by three ...